The storied success of sildenafil has undeniably shaped the pharmaceutical landscape. However, investing in companies heavily focused on copycat drugs and the declining patent protection surrounding this https://johsocial.com/story12051954/the-blue-pill-and-drugmakers-a-risky-investment